Ryvu Therapeutics SA has disclosed protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.

Jeil Pharmaceutical Co. Ltd. has identified son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.

Kurome Therapeutics Inc. along with the Cincinnati Children’s Hospital Medical Center and U.S. Department of Health and Human Services have patented interleukin-1 receptor-associated kinase (IRAK) and/or FLT3 (FLK2/STK1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.

Novorex Inc. has patented protein ENL (MLLT1; YEATS1) and protein AF-9 (MLLT3; AF9) inhibitors reported to be useful for the treatment of cancer.

Gilead Sciences Inc. has patented 4'-Thionucleoside analogues acting as viral replication inhibitors reported to be useful for the treatment of HIV infection.

Radionetics Oncology Inc. has discovered drugs targeting follicle-stimulating hormone (FSH) receptors reported to be useful for the diagnosis and treatment of cancer.

Translational Genomics Research Institute has found macrophage stimulating 1 receptor (MST1R; RON) inhibitors reported to be useful for the treatment of cancer, osteoporosis and osteolysis.

Tocris Cookson Ltd., Helmholtz Zentrum fur Infektionsforschung GmbH and University of Lübeck have described proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands covalently bonded to non-structural protein 3 (nsp3; PL-PRO) (SARS-CoV-2; COVID-19 virus) targeting moiety through linker reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

A Jaguahr Therapeutics Pte Ltd. patent describes new aryl hydrocarbon receptor (AhR) antagonists reported to be useful for the treatment of cancer.

Work at Bellbrook Labs LLC has led to the discovery of imidazolyl-alkoxyquinolin-2-amines acting as cyclic GMP-AMP synthase (MB21D1; cGAS) inhibitors.